Jacobio Announces FDA Approves IND Application to Develop KRAS G12C Inhibitor
Jacobio Announces FDA Approves IND Application to Develop KRAS G12C Inhibitor The clinical trials of KRAS G12C inhibitors are expected to enroll patients in the second half of 2021. Jacobio is aiming for the in-house combination therapy of KRAS G12C and SHP2 inhibitors. Inhibitors targeting KRAS G12D and KRAS G12V mutations have lead compounds. News provided by Share this article Share this article BEIJING and SHANGHAI and BOSTON, May 2, 2021 /PRNewswire/ -- Jacobio Pharmaceuticals (1167.HK) has announced the U.S. Food and Drug Administration (FDA) has approved company's Investigational N...